D-011
1,3-二硝基甘油 溶液
1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C3H6N2O7
化学文摘社编号:
分子量:
182.09
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
200-835-2
MDL number:
产品名称
1,3-二硝基甘油 溶液, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
InChI key
ASIGVDLTBLZXNC-UHFFFAOYSA-N
InChI
1S/C3H6N2O7/c6-3(1-11-4(7)8)2-12-5(9)10/h3,6H,1-2H2
SMILES string
OC(CO[N+]([O-])=O)CO[N+]([O-])=O
grade
certified reference material
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in acetonitrile
technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
application(s)
pharmaceutical (small molecule)
format
single component solution
storage temp.
−20°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
General description
1，3-二硝基甘油是药物血管扩张剂硝酸甘油的主要血浆代谢产物。该经认证的加标溶液®适用于药学研究或临床毒理学中基于色谱或质谱的应用。硝酸甘油用于治疗心脏病，例如心绞痛和慢性心力衰竭。
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Danger
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2
存储类别
3 - Flammable liquids
wgk
WGK 2
flash_point_f
35.6 °F - closed cup
flash_point_c
2 °C - closed cup
法规信息
危险化学品
此项目有
Ivan S de la Lande et al.
European journal of pharmacology, 486(2), 201-207 (2004-02-21)
The influence of the endothelium on glyceryl trinitrate metabolism and relaxation and the relationship to tolerance induced by transdermal glyceryl trinitrate was explored in rat aorta. Metabolism was assessed in artery segments incubated with glyceryl trinitrate (1.0 microM) for 2
M Gumbleton et al.
Journal of pharmacokinetics and biopharmaceutics, 21(5), 515-532 (1993-10-01)
The organic nitrate 1,3-glyceryl dinitrate (1,3-GDN) is one of the primary dinitrate metabolites of the antianginal agent nitroglycerin (GTN). Investigational New Drug Approval was sought to administer oral solution doses of 1,3-GDN to a small number (n = 3) of
R C Jewell et al.
Pharmaceutical research, 9(10), 1284-1289 (1992-10-01)
The FDA Cooperative Efficacy Study of transdermal nitroglycerin utilized a combination of marketed products over a wide dose range. Unfortunately, plasma nitroglycerin concentrations were not determined. The current study was conducted to assess plasma nitrate concentrations after transdermal doses of
B Auclair et al.
Therapeutic drug monitoring, 20(6), 607-611 (1998-12-16)
The purpose of this study was to assess the ability of our previously constructed pharmacokinetic (PK) model to describe nitroglycerin (GTN), 1,2-dinitroglycerin (1,2-GDN), and 1,3-dinitroglycerin (1,3-GDN) plasma concentrations after a single-dose application of a GTN transdermal matrix delivery system. GTN
T Fujii et al.
Biological & pharmaceutical bulletin, 19(8), 1093-1096 (1996-08-01)
Nitroglycerin (GTN) has been used as the drug of choice in the treatment of angina pectoris. It has been shown that some glutathione S-transferases (GSTs) catalyze the metabolic conversion from GTN to glyceryl dinitrates (GDNs). In this study, we examined
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持